# SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

> **NCT01352520** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 79 (actual)

## Conditions studied

- CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma
- Lymphoma, Primary Cutaneous Anaplastic Large Cell
- Lymphomatoid Papulosis
- Mycosis Fungoides
- Skin Lymphoma
- Cutaneous Lymphomas
- Lymphoma
- Hematologic Disorder

## Interventions

- **DRUG:** SGN-35

## Key facts

- **NCT ID:** NCT01352520
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-06
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-01-31
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01352520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01352520, "SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01352520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*